Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
6.40M | 6.17M | 18.14M | 39.02M | 10.99M | 6.91M | Gross Profit |
-3.25M | 4.79M | -55.56M | 37.59M | 9.23M | -40.57M | EBIT |
-91.40M | -76.32M | -78.10M | -65.46M | -73.52M | -57.81M | EBITDA |
-75.09M | -68.40M | -70.99M | -61.86M | -71.64M | -57.81M | Net Income Common Stockholders |
-76.57M | -69.92M | -72.85M | -69.46M | -77.35M | -65.21M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
90.83M | 122.62M | 126.00M | 146.91M | 155.32M | 123.27M | Total Assets |
105.53M | 131.71M | 144.40M | 195.42M | 204.49M | 137.08M | Total Debt |
3.36M | 1.29M | 8.72M | 2.19M | 2.61M | 2.98M | Net Debt |
-28.44M | -35.04M | -17.56M | -28.59M | -106.67M | -49.27M | Total Liabilities |
32.79M | 34.34M | 38.38M | 58.57M | 35.05M | 35.11M | Stockholders Equity |
72.74M | 97.37M | 106.02M | 136.85M | 169.44M | 101.97M |
Cash Flow | Free Cash Flow | ||||
-44.53M | -65.03M | -86.94M | -35.87M | -68.34M | -51.67M | Operating Cash Flow |
-58.71M | -64.85M | -85.94M | -35.36M | -67.53M | -51.44M | Investing Cash Flow |
22.45M | 22.95M | 50.77M | -74.94M | -12.68M | -14.91M | Financing Cash Flow |
30.00M | 52.00M | 30.65M | 31.81M | 137.24M | 86.75M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $907.64M | ― | -63.56% | ― | 270.02% | 32.69% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
52 Neutral | $686.80M | ― | -33.48% | ― | -25.88% | -29.16% | |
50 Neutral | $666.51M | ― | -79.02% | ― | -50.69% | 8.01% | |
50 Neutral | $728.30M | ― | -15.59% | ― | -35.41% | -12.26% | |
45 Neutral | $843.85M | ― | -119.66% | ― | ― | -551.08% | |
40 Underperform | $330.22M | ― | -60.45% | ― | ― | 6.99% |
On May 21, 2025, Arbutus Biopharma Corporation held its Annual General Meeting of Shareholders, where shareholders elected the company’s director nominees, approved executive compensation, and appointed Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are pivotal for Arbutus Biopharma’s governance and operational transparency, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (ABUS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
On May 7, 2025, Arbutus Biopharma presented data at the EASL Congress 2025, showcasing the potential of imdusiran, an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor, in treating chronic hepatitis B (cHBV). The late-breaker poster highlighted that imdusiran, when combined with VTP-300 and low dose nivolumab, achieved a functional cure in some cHBV patients. The Phase 1a/1b trial of AB-101 demonstrated safety and high receptor occupancy without liver dysfunction. These findings suggest promising advancements in HBV treatment, potentially impacting Arbutus’s market position and offering hope for stakeholders in addressing the significant unmet medical need of cHBV.
Arbutus Biopharma Corporation announced the termination of two key executives, Karen Sims, Chief Medical Officer, and David Hastings, Chief Financial Officer, in March 2025. Both executives have entered into separation and consulting agreements with the company, allowing them to extend the exercise period of their stock options for up to a year post-termination. Additionally, Arbutus Biopharma is involved in a legal dispute with Moderna, Inc. over patent infringement related to Moderna’s COVID-19 vaccine, with the trial date moved to September 29, 2025.